| Magnitude and dynamics of the T-cell response to SARS-CoV-2 infection at both individual and population levels TM Snyder, RM Gittelman, M Klinger, DH May, EJ Osborne, R Taniguchi, ... MedRxiv, 2020 | 191 | 2020 |
| A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target A Ghelli Luserna di Rorà, C Cerchione, G Martinelli, G Simonetti Journal of Hematology & Oncology 13 (1), 126, 2020 | 172 | 2020 |
| A large-scale database of T-cell receptor beta (TCRβ) sequences and binding associations from natural and synthetic exposure to SARS-CoV-2 S Nolan, M Vignali, M Klinger, JN Dines, IM Kaplan, E Svejnoha, T Craft, ... Research square, 2020 | 163 | 2020 |
| A review of clinical outcomes of CAR T-cell therapies for B-acute lymphoblastic leukemia M Martino, C Alati, FA Canale, G Musuraca, G Martinelli, C Cerchione International Journal of Molecular Sciences 22 (4), 2150, 2021 | 86 | 2021 |
| CAR-T cell therapy: a potential new strategy against prostate cancer G Schepisi, MC Cursano, C Casadei, C Menna, A Altavilla, C Lolli, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 82 | 2019 |
| Immunotherapy in acute myeloid leukemia: where we stand A Isidori, C Cerchione, N Daver, C DiNardo, G Garcia-Manero, ... Frontiers in oncology 11, 656218, 2021 | 78 | 2021 |
| Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 … A Romano, NL Parrinello, C Vetro, A Chiarenza, C Cerchione, M Ippolito, ... Annals of hematology 97, 1009-1018, 2018 | 63 | 2018 |
| IDH1/IDH2 inhibition in acute myeloid leukemia C Cerchione, A Romano, N Daver, C DiNardo, EJ Jabbour, M Konopleva, ... Frontiers in oncology 11, 639387, 2021 | 57 | 2021 |
| Daratumumab for the management of newly diagnosed and relapsed/refractory multiple myeloma: current and emerging treatments M Offidani, L Corvatta, S Morè, D Nappi, G Martinelli, A Olivieri, ... Frontiers in Oncology 10, 624661, 2021 | 57 | 2021 |
| Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with … N Pugliese, M Di Perna, I Cozzolino, G Ciancia, G Pettinato, P Zeppa, ... Annals of hematology 96, 627-637, 2017 | 50 | 2017 |
| Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM … SW Wong, N Bar, L Paris, CC Hofmeister, M Hansson, A Santoro, ... Blood 140 (Supplement 1), 400-402, 2022 | 49 | 2022 |
| The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents A Romano, N Laura Parrinello, C Cerchione, M Letizia Consoli, M Parisi, ... Blood Cancer Journal 7 (12), 649, 2017 | 44 | 2017 |
| Bendamustine plus Rituximab versus R‐CHOP as first‐line treatment for patients with Follicular Lymphoma grade 3A: evidence from a multicenter, retrospective study P Mondello, N Steiner, W Willenbacher, C Cerchione, D Nappi, E Mauro, ... The oncologist 23 (4), 454-460, 2018 | 43 | 2018 |
| 18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study R Fonti, L Pace, C Cerchione, L Catalano, B Salvatore, S De Luca, ... Clinical nuclear medicine 40 (4), 303-308, 2015 | 38 | 2015 |
| A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: a … M Picardi, R Della Pepa, C Cerchione, N Pugliese, C Mortaruolo, ... Clinical Lymphoma Myeloma and Leukemia 19 (4), e184-e194, 2019 | 33 | 2019 |
| PET/CT in multiple myeloma: beyond FDG F Matteucci, G Paganelli, G Martinelli, C Cerchione Frontiers in oncology 10, 622501, 2021 | 32 | 2021 |
| ACE2 and TMPRSS2 potential involvement in genetic susceptibility to SARS-COV-2 in cancer patients S Ravaioli, M Tebaldi, E Fonzi, D Angeli, M Mazza, F Nicolini, A Lucchesi, ... Cell transplantation 29, 0963689720968749, 2020 | 29 | 2020 |
| Enasidenib and ivosidenib in AML. MP Martelli, G Martino, V Cardinali, B Falini, G Martinelli, C Cerchione Minerva Medica 111 (5), 411-426, 2020 | 29 | 2020 |
| Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? R Maltoni, S Ravaioli, G Bronte, M Mazza, C Cerchione, I Massa, W Balzi, ... Translational Oncology 15 (1), 101300, 2022 | 28 | 2022 |
| Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience M Martino, A Pitino, M Gori, B Bruno, A Crescimanno, V Federico, ... Frontiers in oncology 11, 740079, 2021 | 28 | 2021 |
